Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system

International audienc

Allergic contact dermatitis to sucrose stearate in a facial moisturizing cream

International audienceA 13-year-old boy, with a history of atopic dermatitis during infancy, was referred for the evaluation of facial itchy, erythematous, and papular skin lesions. Because orthodontic metallic brackets had been placed the week before, his parents initially suspected allergic contact dermatitis to nickel or to a related metal. However, history revealed that, at the same time, the boy had started using a facial moisturizing cream two times a day because of dry skin. Following discontinuation of the cream, the dermatitis had spontaneously resolved within 2 weeks

A new source for isothiazolinone contact allergy in traditional, non‐digital photography

International audienc

Allergic contact dermatitis caused by Magnolia officinalis bark extract in a facial anti-ageing cream

International audienc

Allergic contact dermatitis in response to cetearyl glucoside from a topical drug

International audienc

Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump

Background: The frequency of allergic contact dermatitis caused by (meth)acrylates is increasing worldwide, and isobornyl acrylate (IBOA) has been identified as a culprit sensitizer in FreeStyle Libre, a medical device used by diabetic patients. Objectives: To report on 4 patients sensitized to IBOA contained in OmniPod, a new, tubeless insulin pump, and to describe the clinical and chemical analytical work-up. Method: Four patients with eczematous skin eruptions after using OmniPod, including 2 with previous adverse skin reactions to FreeStyle Libre, were patch tested with a baseline series and additional (meth)acrylates, including IBOA in several concentrations and/or vehicles. Gas chromatography-mass spectrometry (GC-MS) was used to identify the presence of IBOA in OmniPod. Results: All patients were shown to be sensitized to IBOA. GC-MS identified IBOA in OmniPod, with the highest concentrations being found in the unit itself and not in the adhesive patch. Conclusions: The OmniPod tubeless insulin pump is another source of IBOA, and its use may lead to primary sensitization to this acrylate, or may provoke elicitation of allergic contact dermatitis in previously sensitized patients. Our cases highlight the need to obtain satisfactory cooperation from pharmaceutical companies involved in the manufacture of these widely used medical devices